HARRISBURG – PA Attorney General Dave Sunday announced a lawsuit against some pharmaceutical companies and PBMs (pharmacy benefit managers) regarding collusion to manipulate insulin price markets causing increasing out-of-pocket costs for Pennsylvanians. Named as defendants are pharmaceutical manufacturers Eli Lilly and Company, Novo Nordisk Inc., and Sanofi-Aventis US LLC, and numerous PBMs, including Express Scripts, CVS Caremark, and Optum RX. The lawsuit alleges the parties conspired to artificially inflate insulin prices by over 1,000%. About 1.3 million Pennsylvanians live with diabetes, and an additional 3.5 million more have prediabetes. Diagnosed diabetes costs PA an estimated $16.4 billion per year. The lawsuit alleges that the manufacturers and PBMs engaged in deceptive market practices to create abnormally high prices. The complaint seeks injunctive relief that would require structural changes to ensure the companies lower costs to fair market prices and enable options for patients. In addition to injunctive relief, the complaint seeks restitution for Pennsylvanians who were harmed by the conduct, as well as civil penalties and costs.
